Skip to content

This Site is Intended for Healthcare Professionals Only

Search AI Powered

Latest Stories

Research raises concerns about impact of Ramadan fasting on diabetics during lockdown

Lack of physical activity and poor sleep patterns during Ramadan can affect the health of people with Type 2 diabetes, a latest study has shown.

A research by De Montfort University Leicester has also raised concern that the coronavirus lockdown could lead to a dramatic fall in physical activity compared to previous Ramadan festivals.


The patients with Type 2 diabetes should seek medical advice as to whether they take part or not in the Ramadan fasting, the experts have opined.

Dr Abdullah Alghamdi and Professor Parvez Haris have found that lack of physical activity and small periods of night time sleep during Ramadan can affect the way the body uses insulin and glucose.

Dr Alghamdi, under the guidance of Haris, carried out the study in Saudi Arabia on 16 women and 20 men with type-two diabetes.

The research concluded that “the low physical activity and the poor sleep behaviours of the study’s participants may worsen their diabetes” and furthermore this could “minimise the potential of Ramadan intermittent fasting as a non-pharmacological therapy” for managing or even reversing Type 2 diabetes.

Dr Alghamdi said anyone with Type 2 diabetes should seek medical advice about whether they can take part in the fasting.

The researchers have concluded that previously published research had shown intermittent fasting can benefit the health of Type 2 diabetics – but a total lack of physical activity could negate this.

More For You

Germany's BioNTech to buy CureVac to boost cancer research

Both biotech companies have been working for years in the area of mRNA vaccines and treatments

Germany's BioNTech to buy CureVac to boost cancer research

Germany's BioNTech is buying domestic rival CureVac for $1.25 billion, bringing together two pharmaceutical firms specialised in mRNA technology with the goal of advancing cancer treatments.

BioNTech, which developed the first coronavirus vaccine to be approved in the West along with US pharmaceutical giant Pfizer, said the acquisition would "bring together complementary capabilities and leverage technologies".

Keep ReadingShow less
Amandeep Doll RPS  New Director of England

Amandeep Doll

RPS announces new director of England

Amandeep Doll has been named as the new director for England at the Royal Pharmaceutical Society (RPS).

The role of Director for England drives professional leadership for the pharmacy profession in England, and leads on national policy development and advocacy across England, in partnership with the English Pharmacy Board.

Keep ReadingShow less
NHS to invest millions to boost enhanced treatment for sickle cell patients

Approximately 17,000 people live in England with sickle cell disease

Pic credit: istock

NHS to invest millions to boost enhanced treatment for sickle cell patients

The Department of Health and Social Care has announced that it will invest £9 million towards the treatment of sickle cell patients.

Approximately 17,000 people live in England with sickle cell disease. Nearly 250 new cases of this inherited blood disorder is reported annually.

Keep ReadingShow less
NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients

An estimated 6,000 cases of multiple myeloma is diagnosed in the UK each year.

Pic credit: istock

NHS leads the world with new ‘trojan horse’ therapy for blood cancer patients


NHS England has become the first in the world to introduce a ‘trojan horse’ therapy for the victims of blood cancer with the ground-breaking treatment slowing down the illness three-times more than existing treatments.

Keep ReadingShow less
Call to improve inclusivity in clinical research

Ethnic minority adults continue to be underrepresented in clinical trials.

iStock

Call to improve inclusivity in clinical research

A NEW report has called for the participation of a wide range of diverse communities in clinical research to make sure that the medicines meet the needs of the UK's increasingly diverse population.

The report ‘Achieving inclusivity in clinical research’, prepared by the Association of the British Pharmaceutical Industry (ABPI) and the Association of Medical Research Charities (AMRC), highlights the long-standing challenges in ensuring diversity in clinical trials.

Keep ReadingShow less